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Detoxification
lthough agonist maintenance therapies yield bet-
ter outcomes for most opioid addicts,
1-3 they continue to
seek opioid withdrawal primarily to lower the cost of their
habit or as pretreatment before the residential therapeu-
tic community or opioid antagonist maintenance. High
relapse rates are probably less a function of withdrawal
method and due more to reasons for seeking detoxifica-
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While opioid dependence has more treatment agents available than other abused drugs, none are curative. They can,
however, markedly diminish withdrawal symptoms and craving, and block opioid effects due to lapses.
The most effective withdrawal method is substituting and tapering methadone or buprenorphine. -2 Adrenergic
agents can ameliorate untreated symptoms or substitute for agonists if not available. Shortening withdrawal by pre-
cipitating it with narcotic antagonists has been studied, but the methods are plagued by safety issues or persisting
symptoms. Neither the withdrawal agents nor the methods are associated with better long-term outcome, which
appears mostly related to post-detoxification treatment.
Excluding those with short-term habits, the best outcome occurs with long-term maintenance on methadone or
buprenorphine accompanied by appropriate psychosocial interventions. Those with strong external motivation may
do well on the antagonist naltrexone. Currently, optimum duration of maintenance on either is unclear. Better agents
are needed to impact the brain changes related to addiction.     
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oped during dependence.Those who complete detoxifica-
tion tend to have longer times to relapse than dropouts.
4,5
Clinical issues
Symptom severity is related to the specific narcotic used
(short-acting yields more severe withdrawal); amount
used;duration of use (at least 2 to 3 weeks,daily);and set
and setting factors.Withdrawal phenomena are generally
the opposite of acute agonist effects. Withdrawal from
heroin begins with anxiety and craving 8 to 12 hours after
the last dose,reaches its peak between 36 and 72 hours,
and subsides substantially within 5 days.Methadone with-
drawal begins at 24 to 36 hours,peaks at 96 to 144 hours,
and may last for weeks.Individuals differ markedly,both
as to which symptoms are present and their severity.
6
Acute opioid withdrawal symptoms are followed by a pro-
tracted abstinence syndrome,including dysphoria,fatigue,
insomnia and irritability,for 6 to 8 months.
7
Withdrawal agents
Methadone
Methadone is orally effective,long-acting—thus produc-
ing smoother withdrawal—and safe,if care is taken with
initial dosing.
Because 40 mg of methadone has been a fatal dose in
some nontolerant individuals,the initial dose should be
less,eg,10 to 20 mg.If withdrawal symptoms are not sup-
pressed within 1 hour,more can be given,but in general
the initial dose should not exceed 30 mg,and the total 24-
hour dose should not exceed 40 mg the first few days.In
a nontolerant individual, an initial tolerated dose can
become risky if continued beyond 2 days because of ris-
ing methadone blood levels.
8The clinician should be alert
for signs of drowsiness or motor impairment.
Physical dependence can be ascertained by:(i) waiting
until the patient develops withdrawal signs and symp-
toms; or (ii) precipitating withdrawal via naloxone (if
pregnancy has been ruled out).
After the patient is stabilized, the dosage is gradually
reduced,either by decreasing the methadone 5 mg/day
until zero dosage is reached, or decreasing 10 mg/day
until 10 mg is reached and then by 2 mg/day.
9
Inpatient methadone substitution and taper is usually
accomplished in 5 to 7 days, and has a retention rate of
80%;with outpatient detoxification it takes longer to min-
imize withdrawal symptoms and to decrease dropout and
relapse,but only about 20% complete it.
10 Lingering pro-
tracted withdrawal symptoms can be helped by clonidine.
Buprenorphine
The Food and Drug administration (FDA) approved sub-
lingual buprenorphine in 2002 for office-based treatment
for detoxification or maintenance of opioid dependence.
Buprenorphine is long-acting,safe,and effective by the
sublingual route,but may precipitate withdrawal symp-
toms if given too soon after an opioid agonist. If the
patient has withdrawal symptoms and has waited at least
12 hours after short-acting opioids and 36 hours after
methadone,buprenorphine usually serves to relieve these
symptoms and is less likely to precipitate withdrawal.It
may also be useful in emergency department settings.
11
Heroin detoxification is managed by administering
buprenorphine 2 to 4 mg sublingually after the emer-
gence of mild-to-moderate withdrawal.A second dose of
buprenorphine 2 to 4 mg may be administered approxi-
mately 1 to 2 hours later,depending on the patient’s com-
fort level.Usually a total of 8 to 12 mg of buprenorphine
is sufficient the first day.For most patients,a slow taper
over a week or so is a safe and well tolerated strategy.
Any buprenorphine dose that worsens withdrawal symp-
toms suggests the buprenorphine dose is too high com-
pared with the level of withdrawal.The symptoms should
be treated with clonidine, and further buprenorphine
doses withheld for at least 6 to 8 hours.Buprenorphine,
even at doses of 16 mg, may not suppress all signs and
symptoms of withdrawal if the patient had a very severe
habit,
12 but most symptoms respond to adding clonidine
0.1 mg every 4 to 6 hours.
The duration of withdrawal from abrupt buprenorphine
cessation is variable even from patient to patient.In one
study,about one fifth of the patients maintained on daily
buprenorphine 16 mg sublingually for 10 days experi-
enced significant withdrawal symptoms after abrupt stop-
ping.
13 Buprenorphine can be used to transfer patients
from methadone maintenance to buprenorphine main-
tenance or to a drug-free state.The patient needs to be
at least in mild withdrawal,and the methadone dose 40
mg or less for at least a week prior to beginning
buprenorphine.
14
Another way of using buprenorphine is for rapid with-
drawal.A randomized study in heroin addicts
15 compared
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fication,followed by antagonist induction.The buprenor-
phine group received a single dose of 8 mg on day 0,
none on day 1, and naltrexone on day 2 at 12.5 mg,
titrated up to 50 mg/day over 2 days.Symptom severity
and retention at 1 month were similar in both groups.
Another study also found that prior buprenorphine
preparation markedly decreased post procedure mor-
bidity.
16
A recent systematic review compared buprenorphine to
other detoxification strategies.
17 Compared with cloni-
dine,buprenorphine was found to be more effective in
ameliorating withdrawal symptoms; patients stayed in
treatment longer,especially in outpatient settings,and
were more likely to complete withdrawal.When com-
pared with methadone-aided withdrawal,buprenorphine
produced no significant difference in treatment comple-
tion,or severity of withdrawal,but withdrawal symptoms
resolved more quickly.
Other detoxification agents and methods
Clonidine
The antihypertensive,α2-adrenergic agonist drug clonidine
has been used to facilitate opioid withdrawal in both inpa-
tient and outpatient settings for over 25 years.
18-21 It works
by binding to α2 autoreceptors in the locus coeruleus and
suppressing its hyperactivity during withdrawal.Doses of
0.4 to 1.2 mg/day or higher reduce many of the autonomic
components of the opioid withdrawal syndrome,but symp-
toms such as insomnia, lethargy, muscle aches, and rest-
lessness may not be adequately handled.
22
Compared with methadone-aided withdrawal,clonidine
has more side effects,especially hypotension,but is less
likely to lead to post-withdrawal rebound.Dropouts are
more likely to occur early with clonidine and later with
methadone.In a study of heroin detoxification,buprenor-
phine did better on retention,heroin use,and withdrawal
severity than the clonidine group.
12 Since clonidine has
mild analgesic effects,added analgesia may not be needed
during the withdrawal period for medical opioid addicts.
Lofexidine
Hypotensive effects may limit the optimal dosing of
clonidine for opioid withdrawal.Lofexidine,an analogue
of clonidine,has been approved in the UK and may be as
effective as clonidine for opioid withdrawal with less
hypotension and sedation.
23,24 Combining lofexidine with
low-dose naloxone appears to improve retention symp-
toms and time to relapse.
4,25-28
Supportive measures
Insomnia is both common and debilitating.Clonazepam,
trazodone, and zolpidem have all been used for with-
drawal-related insomnia,but the decision to use a ben-
zodiazepine needs to be made carefully, especially for
outpatient detoxification.
Treatments for ancillary withdrawal symptoms include
nonsteroidal anti-inflammatory drugs (eg,ibuprofen or
ketorolac tromethamine) for muscle cramps or pain;bis-
muth subsalicylate for diarrhea; prochlorperazine or
ondansetron for nausea and vomiting;and α2-adrenergic
agents (eg,clonidine) for flu-like symptoms.Vitamin and
mineral supplements are often given.
Rapid detoxification methods
Clonidine-naltrexone detoxification 
This method
29-31 combines a rapid,precipitated withdrawal
by naltrexone producing severe withdrawal symptoms,
with high doses of clonidine and benzodiazepines before
and after the naltrexone to ameliorate the symptoms.
While shortening withdrawal to 2 to 3 days, evidence is
lacking of longer abstinence or naltrexone retention.
32
Rapid opioid withdrawal under general anesthesia
To decrease further the time needed for withdrawal,a rapid
detoxification procedure using general anesthesia was
developed
33 and gradually improved.
34-37A variety of med-
ications have been used,including naltrexone or nalme-
fene,propofol anesthesia or heavy midazolam sedation,the
antiemetic ondansetron,the antidiarrheal octreotide,and
clonidine and benzodiazepines for other withdrawal symp-
toms, and has been carried out on either an inpatient or
outpatient basis. Post-procedure therapy varies widely.
Claims of high rates of abstinence months after detoxifica-
tion have been made,but no objective verification exists,
and the samples are not representative.
38 Significant with-
drawal symptoms may persist for days or even weeks after
the procedure in humans
15,39,40 or in rats,
41 and there appears
to be no longer-term improved outcome at 1 to 3 months
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15,42,43 Internationally,over one dozen deaths have been
reported, usually within 72 hours of the procedure, with
pulmonary edema a common complication.
44-47
Pregnancy
Illicit opioid use during pregnancy can have numerous
harmful effects on the woman, fetus, and neonate.
Residential abstinent treatment is usually not available.
Methadone maintenance is thus the standard approach.
48
While the infant will be physically dependent on
methadone and about half need to be withdrawn,no birth
defects are associated with such exposure,if prenatal care
is adequate.Withdrawal from methadone maintenance is
usually not preferable,but if carried out it should occur
during the second trimester at no greater than 5 mg/week.
Methadone metabolism is increased during pregnancy,and
plasma half-life decreased.The clinician must balance the
risk of illicit opioid use if the dose is too low,and the risks
of the neonatal abstinence syndrome (NAS) if the dose is
too high.This can be somewhat ameliorated by split dos-
ing.Studies of pregnant methadone-maintained women
found decreased narcotic use and improved health and
prenatal care.Fetal growth and perinatal outcomes also
improved. These benefits diminish with continued
use/abuse of licit (alcohol and tobacco) or illicit (cocaine
and marijuana) substances.
49
Maintenance on buprenorphine is a more recent devel-
opment with published reports of over 300 pregnancies,
with good fetal outcomes.Buprenorphine appears com-
parable to methadone on outcome measures as assessed
by NAS and maternal and neonatal safety.
50-54 One study
52
reported shorter hospital stays for babies born to
buprenorphine-maintained mothers in comparison to
methadone. Long-term effects beyond the neonatal
period,however,are not sufficiently studied.
Agonist maintenance: methadone
Pioneering work by Dole and Nyswander in the 1960s
55-57
provided the initial scientific basis for using the long-act-
ing opioid agonist methadone for maintenance.
Numerous studies since then
58-62 have demonstrated that
methadone maintenance of opioid addicts substantially
reduces mortality and morbidity,the risk of new human
immunodeficiency virus (HIV) infection,criminal activ-
ity, and illicit opioid use, especially when used with
enhanced ancillary services.
63 Unfortunately,many pro-
grams do not provide these services, both because of
decreased government funding and increased private
ownership.In the US,there are over 240 000 individuals
maintained on methadone,while in some other countries,
eg, Russia, government opposition to agonist mainte-
nance prevents its use,even when high HIV rates exist.
Federal regulations
With a few exceptions, methadone may only be dis-
pensed for opioid detoxification or maintenance treat-
ment by opioid treatment programs certified by the
Substance Abuse and Mental Health Administration
(SAMHSA) and approved by the appropriate state
agency. Depending on criteria such as continued illicit
drug use and employment,an increasing number of take-
home doses is permitted,up to a maximum of a 1-month
supply after 2 years or longer.
Pharmacology
While heroin is short-acting and relatively ineffective
orally,methadone is a long-acting,and orally effective,
opioid.It is excreted primarily in the urine and is an ago-
nist at µ and δ opiate receptors.
Methadone is primarily metabolized through cytochrome
P450 (CYP) enzymes, predominantly involving the
CYP3A4 pathway.Drugs that increase the P450 enzymes,
such as the retroviral agents for treating HIV, may
increase methadone metabolism and lead to withdrawal
symptoms,even in stable maintained patients.In contrast,
drugs that inhibit these enzymes,such as some selective
serotonin reuptake inhibitor (SSRI) antidepressants,may
increase methadone levels and sedation.
64-68 Effects are
more likely early in treatment before plasma levels have
stabilized.
69 Physicians using methadone are advised to
consult tables of drug interactions for complete listings.
Dosing
Methadone’s plasma half-life,once stabilized,averages
24 to 36 hours
70 with a range of 13 to 50 hours,making it
a useful once-daily maintenance medication compared
with morphine or heroin.However,up to 10 days may be
needed for such a steady state and before that, new
patients,either in maintenance or given methadone for
analgesia,are at risk of fatal overdose.
8,71 Doses should
not exceed 40 mg/day the first day of dosing or be
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every 2 to 3 days.Individual differences in rate of metab-
olism may produce complaints of withdrawal symptoms,
even in those on a stable dose.
Doses of 30 to 40 mg of methadone prevent most with-
drawal symptoms and craving,but are not high enough
to block the reinforcing effects of high doses of potent
heroin.Doses of greater than 80 mg/day are associated
with fewer positive urine tests than 40 mg,and programs
with average doses of 80 to 120 mg have consistently bet-
ter results than those with lower average doses.
72-75 As
heroin potency increased, the average daily dose of
methadone doubled in the 1990s.
76 Some programs today
dose as high as 350 mg/day using the rationale of indi-
vidual metabolic differences.Such doses have at times
been associated with increased street sales.
Safety
Studies of methadone maintenance have not found long-
term damage to the heart, kidneys, liver, or lungs.
77-79
Further,long-acting maintenance medications normalize
the neuroendocrine alterations induced by short-acting
opioids and with minimal psychoactive impairment,
80
unless accompanied by high concomitant use of benzo-
diazepines and alcohol found in many methadone pro-
grams. The most common side effects of methadone
maintenance are constipation,sweating,urinary reten-
tion,and dose-related orgasm dysfunction in men.
Methadone overdose has been a problem with acciden-
tal ingestion by children (10 mg has been a fatal dose),
use by nondependent opioid users experimenting with
methadone,or during initiation of maintenance.While
rapid treatment of overdose with narcotic antagonists
can lead to full recovery,it is important to keep such indi-
viduals under observation for at least 24 hours and fol-
low the initial naloxone treatment with a long-acting
antagonist such as nalmefene.Death may occur even 24
hours or more after the methadone intake.Other factors
associated with increased risk of overdose include med-
ications that inhibit CYP3A4,use of alcohol or benzodi-
azepines,or liver disease.The possibility of cardiac con-
duction defects with methadone, especially at doses
higher than 120 mg/day,
81 led to a black-box warning for
methadone in December 2006.
Driving by patients on long-term methadone mainte-
nance has not been found to be impaired,
82 but patients
should be warned about driving after using alcohol,illicit
drugs, or sedating medications. As with patients with-
drawing from alcohol, patients beginning methadone
maintenance may have some short-term cognitive
impairment early in treatment.
83
Nonpharmacologic components 
Methadone is a medication,not a treatment.To achieve
its potential, methadone maintenance should be com-
bined with counseling aimed at lifestyle change.A clas-
sic study
63 demonstrated this by randomly assigning
patients to minimal counseling,standard drug counsel-
ing, or enhanced services while maintaining them on
identical standard daily methadone doses.Patients in the
minimal counseling group had substantially higher illicit
cocaine and opioid use than the other 2 groups. By 12
weeks, 69% of the patients in the minimal counseling
group had 8 consecutive weeks of illicit opiate or cocaine
use or three emergency situations compared with 41% of
those receiving standard counseling and 19% of those
receiving enhanced services. Recently a number of
behavioral approaches,eg,contingency contracting and
voucher incentives,have also shown efficacy,especially if
staff is appropriately trained.
84
While appropriate therapy is better than no therapy,
some randomized studies have suggested that methadone
alone is better than being on a waiting list.
85,86 Such
methadone maintenance is permitted for up to 120 days
in areas with long waiting lists.
Co-occurring disorders
There is high prevalence of comorbid psychiatric and
substance abuse disorders among opioid addicts,as well
as diseases common because of drug lifestyle, eg,
acquired immune deficiency syndrome (AIDS),hepati-
tis B or C,and tuberculosis.
87 Since treatments for HIV
and hepatitis C can stabilize these disorders,methadone
programs need to screen and refer patients for medical
treatment,as well as providing or referring for psychiatric
disorders if patients are to adequately recover.
Pain 
Over one third of methadone maintenance patients are
estimated to have moderate-to-severe chronic pain.They
have become tolerant to methadone’s analgesic proper-
ties and may even have increased pain sensitivity.
88
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459Treating methadone-maintained patients for acute pain
with opioid analgesics has not been found to lead to
relapse or higher methadone doses post-treatment.
89The
regular,daily methadone dose should be continued,and
analgesic medications including nonopioid analgesics or
short-acting opioids added as clinically indicated.
90,91 Since
methadone occupies less than one third of the µ opioid
receptors,unoccupied receptors are available for analgesic
response.
92 However, methadone-maintained patients
might require higher doses or more frequent administra-
tion of opioid analgesics than nonmaintained patients.
Office-based methadone maintenance treatment
Office-based methadone maintenance has been permit-
ted on a limited basis for patients who have been stable
for at least a few years.In general,patients on this “med-
ical maintenance”have been successful
93,94 but a number
increased their use of illicit drugs.
95-98While the number
of patients on methadone maintenance has increased to
240 000, there remain many parts of the country with
inadequate availability and long waiting lists.
Discontinuation of methadone maintenance
How long patients should remain on methadone mainte-
nance is controversial.Those on methadone do better than
those who stop,with relapse common in this latter group.
Methadone maintenance’s contributions to improved
health and functioning may increase slowly over time,but
markedly decreases when methadone is discontinued.The
risk of relapse following withdrawal from methadone
maintenance is high,even for patients who have been on
it for long periods and have made substantial changes in
lifestyle.In this era of AIDS,the risk of serious adverse
consequences following relapse suggest that for many
patients lifetime maintenance may be necessary.
99-101
There is substantial political opposition to methadone
maintenance,which manifests itself in problems locating
clinic sites,lack of economic support,and family opposi-
tion.The clinic–based nature of the programs,which mix
stable patients and newly maintained patients,along with
inadequate staffing, and minimal incentives for patient
change,can lead to a culture of continued illicit drug use
and chronic unemployment.
94 In spite of many decades of
improving and saving lives, methadone maintenance is
often viewed as perpetuating addiction or being immoral.
The traditional method of withdrawal is decreasing the
methadone dose rapidly until 30 mg is reached,and then
slowly tapering from that,eg 5 mg/week or switching to
clonidine.
102,103 A more recent approach involves trans-
ferring the patient to buprenorphine/naloxone and then
tapering as described in the section on discontinuing
buprenorphine.
103
Partial agonist maintenance
Buprenorphine
Buprenorphine,a Schedule III controlled substance,is a
high affinity partial µ-opioid agonist, κ antagonist, and
ORL-1 receptor agonist.
104 Studies from 1980 on found it
useful for treating opioid withdrawal and dependence.
105-109
Office-based buprenorphine maintenance has already
increased treatment availability for opioid-dependent indi-
viduals and brought into treatment populations that had
been unable or unwilling to attend methadone mainte-
nance clinics,eg,prescription opioid addicts.Prescription
opioid addicts seeking office-based buprenorphine are
likely to present different issues than heroin addicts apply-
ing for methadone maintenance.
110 Primary-care physicians
who have not treated opioid dependence will also present
new challenges to the field.Anecdotal reports describe
patients on buprenorphine as feeling more clear-headed,
more energetic, and more aware of emotions than on
methadone maintenance.
111To diminish possible diversion
to parenteral use, the recommended form of buprenor-
phine is a 4:1 combination with naloxone (Suboxone).The
mono form (Subutex) is used for pregnant women and,at
times,for induction.
Federal regulations
In 2002,the FDA approved buprenorphine for the treat-
ment of opioid dependence in office-based practice.It was
already being used for such treatment in other countries.
Physicians need to receive 8 hours of specialized training
in person or online,and then apply for a waiver from the
Department of Health and Human Services.They are lim-
ited to 30 patients on buprenorphine for the first year,and
can then apply to increase the number to 100.
Pharmacology
Buprenorphine binds to the µ receptor and activates it,
but as the dose increases,there is a ceiling on some opi-
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460oid agonist effects,such as respiratory depression,mak-
ing it safer than a full agonist as far as overdose.This has
been demonstrated by the differential effects on over-
dose deaths in France of methadone and buprenor-
phine.
112The ceiling effect is approximately 32 mg of sub-
lingual buprenorphine,but it may be possible to increase
analgesic effects above that.
Because buprenorphine is best absorbed parenterally
and poorest orally,
113-115 with sublingual bioavailability in
between, and naloxone is poorly absorbed orally but
about 20 times more parenterally,the sublingual combi-
nation tablet yields primarily a buprenorphine effect.If
crushed and injected, both drugs are bioavailable.
114,115
Naloxone will then precipitate opioid withdrawal if the
individual is opioid-dependent,unless only on buprenor-
phine.Buprenorphine alone will also precipitate with-
drawal by displacing other opiates from the receptor.
Individuals who use only buprenorphine can get high
even if they inject the combination product,but it is not
as reinforcing.
116
There have been a number of reports of buprenorphine
abuse in some countries, including France,
117 Finland,
118
Great Britain,
119 and Australia.
120 Only Finland has,since
2004, the combination product. A recent study from
Finland found a very high rate of buprenorphine intra-
venous (IV) use but 75% of such users said they were
using it to self-medicate addiction or withdrawal.Over two
thirds had tried the combination IV but 80% said they had
a “bad experience.”As a result,the street price of the com-
bination was less than half of the mono product.
121
Buprenorphine undergoes metabolism by the liver,pri-
marily by the cytochrome P450 3A4 enzyme system
122,123
but studies have not found clinically significant interac-
tions with HIV medications that interact with this sys-
tem,
124 with the possible exception of atazanavir/reton-
avir.
125 Buprenorphine’s terminal half-life of 37 hours and
slow-onset and offset enables every-other-day dosing,
although that tends not to be the preferred spacing by
patients.Buprenorphine’s high affinity at the µ receptor
means it will block most opioid agonist effects,
126,127 but
because of its ceiling effect,one can override the block-
ade by using higher agonist doses.
128,129
Induction
For practical reasons,buprenorphine induction is usually
done on an outpatient basis,with induction divided into
two visits: initial evaluation for suitability, answering
questions and giving instructions for the second visit;and
actual induction.Induction may take 2 hours or longer,
and patients should not drive that first day.When dis-
tance or other factors prevent two visits, careful tele-
phone preparation is important.
Buprenorphine can displace a full opioid agonist from
the µ receptor,but since it is only a partial agonist there
could be precipitated opioid withdrawal.At induction,
therefore,the addicted patient should be in withdrawal:
off short-acting opioids for at least 12 to 16 hours and
long-acting ones for at least 36 hours.When the patient
is transferring from methadone maintenance, the pro-
gram needs to verify the methadone dose as 40 mg or
less and history of compliance with rules, especially
drug use.
While 4 mg of buprenorphine is often used as the initial
dose,
103 if there is doubt about the patient’s withdrawal
symptoms,the buprenorphine dose should be lowered to
2 mg.If the initial dose of 2 or 4 mg is tolerated,a similar
second dose can be given an hour later and then 4 mg 6
to 8 hours later.The total dose on day 1 usually should
not exceed 8 to 12 mg.If any dose worsens withdrawal
symptoms, the buprenorphine should be temporarily
halted and the symptoms treated with oral clonidine 0.1-
0.2 mg.Once symptoms have improved,the buprenor-
phine can be restarted. It is better to err on the side of
incomplete suppression of withdrawal on day 1 than to
have precipitated withdrawal,which may drive the patient
away.
By day 2 or 3, a dose of 12 to 16 mg is usually reached
and resolves most withdrawal symptoms. Clonidine
can be used to treat residual mild symptoms for a few
days to a week as long as the patient does not
become hypotensive.The most difficult and distress-
ing symptom is usually insomnia. Depending whether
there is a history of benzodiazepine abuse, agents
chosen to treat this include trazodone, zolpidem, or
clonazepam.
The usual maintenance dose is 16 to 24 mg/day although
some patients are comfortable at 8 to 12 mg and others
need 24 to 32 mg. Many patients prefer taking the
buprenorphine in divided doses,two or three times a day,
as opposed to only once.
Patient selection issues
The patient first needs to meet the criteria for opioid
dependence. Abuse of, or dependence on, other sub-
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along with need for sedative detoxification, history of
previous treatments,and psychiatric problems should all
be explored.
Detoxification or maintenance
Many patients initially request buprenorphine detoxifi-
cation and then change their minds a few weeks later and
request maintenance.Given the high relapse rate post-
withdrawal, this request may be reasonable. However,
buprenorphine is relatively easy to detoxify with but
harder to detoxify from.Thus,withdrawal should not be
stretched out longer than 2 to 3 weeks if maintenance is
not the ultimate goal.
Maintenance on buprenorphine vs methadone
If the patient’s lifestyle is unstable,eg,homelessness,or
needs the structure of regular attendance in a dispensing
situation,or needs the wider range of services available
in a comprehensive methadone maintenance program,
or lacks the insurance or financial wherewithal to pay for
buprenorphine medication and therapy,the patient may
be better served by a methadone maintenance program.
Since buprenorphine is a partial µ agonist with maximal
efficacy approximately equal to 70 mg of methadone,it
may not be adequate for some patients. Optimal
methadone doses average around 100 mg/day and some
patients require much higher doses.
129A meta-analysis
130
found that both methadone and buprenorphine mainte-
nance could be equally effective, but there was a wide
variation in the studies covered. A way around this
dilemma is to use a stepped approach whereby patients
would be started on buprenorphine and increased as nec-
essary up to 32 mg/day.If clinical results are inadequate,
the patient would be moved to methadone maintenance
and dosed as needed.
131 For patients who clearly need the
structure of a methadone program,but prefer buprenor-
phine, it could be dispensed by a methadone program
using the same rules as methadone.
Use of buprenorphine vs the buprenorphine/naloxone
combination
It is preferable to maintain patients on the combination
product unless they are pregnant or trying to become so.
Many clinicians prefer the mono form for the initial induc-
tion,either because of concern for possible pregnancy or
so that they do not need to worry about whether unre-
lieved withdrawal symptoms are due to increased amounts
of naloxone being absorbed. The patient should be
switched to the combination form once stable.
Age
While buprenorphine withdrawal or maintenance is legal
above the age of 16,short-term dependence may be bet-
ter handled by withdrawal and intensive counseling.
Other laboratory tests 
In addition to testing for drugs of abuse,patients should
be evaluated at baseline by the usual medical screening
tests,as well as pregnancy,when appropriate,and tests for
hepatitis B,C,HIV,and tuberculosis.Baseline tests can
be carried out by the patient’s own physician or ordered
by the prescribing doctor.
Use of other drugs
The safety of buprenorphine on respiratory depression
can be thwarted by concomitant use of benzodiazepines
or other sedatives,especially when both the buprenor-
phine and the benzodiazepines are injected.A number
of deaths have been reported from France due to this.
112,132
Low-dose oral benzodiazepines used judiciously do not
appear to present the same problem.
The effect of buprenorphine maintenance on cocaine use
in opiate addicts remains unclear.Some clinical studies
have demonstrated efficacy in reducing cocaine use
133,134
while others have been inconclusive
135 or negative.
136
Maintenance
Counseling
Buprenorphine and methadone are medications, not
treatments, and should be combined with appropriate
counseling services.The prescriber does not have to pro-
vide the counseling but convenient access will enhance
compliance.Counseling can be individual,group or fam-
ily therapy,or combinations.However,therapists have
reported that many patients feel so well on buprenor-
phine compared with either methadone or their previous
illicit drug use that they resist counseling.
111
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Drug testing,via “dipsticks”or commercial laboratories,
can detect use of illicit opioids, cocaine, or benzodi-
azepines.The testing strips are easily used in the office
but the standard opiate strips usually do not test for
buprenorphine,methadone,hydrocodone,or oxycodone,
so specific tests for these drugs are necessary to avoid
false-negative results.
103The test frequency and whether
it is scheduled or random is a function of the physician’s
judgment in each case.
Maintenance
Once symptoms of opiate withdrawal and use of other opi-
oids has been significantly decreased or eliminated,the
maintenance phase begins. Dose increases may occur
either because the patient is continuing illicit opioid use
while apparently complying with the buprenorphine
(monitored dosing may be necessary), or because the
patient complains that the dose is not sufficient.Changing
the frequency or scheduling of the buprenorphine doses
may improve the latter.Although buprenorphine has a
long half-life,some patients report better results by dosing
3 times/day,eg,8 mg AM,PM,and late evening.The final
dose is usually 8 to 24 mg/day
103 but some patients appear
to need 32 mg.If illicit opioid use continues in spite of high
buprenorphine doses and therapy,referral for methadone
maintenance or depot naltrexone may be necessary.
Before that final step,it may be worthwhile to try contin-
gency contracting using frequency of visits or weeks pre-
scribed as the reward.
137 Psychiatric problems can be com-
mon (over 50% in one unsolicited sample).
138Appropriate
medications or other approaches might markedly reduce
the illicit drug use and make transferring unnecessary.
Office visits once a week are usually recommended ini-
tially
103 and can be reduced if the dose is stable,illicit drug
use has stopped,and more intense psychological inter-
vention is not needed.However,there may be practical
obstacles to this,such as distance from the physician or
problems paying for the medication and doctor’s visit if
not adequately covered by insurance.Frequency can be
reduced gradually with stable patients to once monthly.
Side effects
Buprenorphine does not appear to cause liver abnor-
malities but,as with other narcotics,side effects such as
constipation,nausea,and decreased sexual interest have
been reported.
139 Unlike methadone, buprenorphine
maintenance does not appear to be associated with elec-
trocardiographic abnormalities.
140 Buprenorphine’s
desirable mood effects compared with methadone
111 may
relate to methadone’s producing a significant opioid
effect lasting from 2 to 5 hours after dosing in main-
tained patients.
141,142 This may interfere with everyday
activities.
Other issues
Acute pain
Acute pain is more difficult to manage with buprenor-
phine compared with a full agonist,but there are a num-
ber of options.These include dividing the daily buprenor-
phine dose into 3 or 4 doses and adding nonopioid
analgesics;adding a full µ opioid analgesic on top of the
buprenorphine dose;switching the patient temporarily
over to a short-acting full µ agonist and increasing the
dose until adequate pain relief occurs;or using nonopi-
oid ways of dealing with pain such as regional or general
anesthesia in a hospital setting.
90,91,143
Chronic pain
Many patients with chronic pain can be treated with
buprenorphine doses of 24 to 32 mg divided into 3 or 4
daily doses and supplemented if necessary by nonopioid
analgesics.If pain relief is not sufficient,or the patient
is resorting to illicit opioid use to control it,transfer to
methadone maintenance may be needed.
Discontinuation of buprenorphine maintenance
While there is no legal limit to the length of buprenor-
phine maintenance,many patients ask to be withdrawn
a few months after being maintained.The usual reasons
are desire to be off all narcotics or the cost.Patients often
have an unrealistic expectation of how easy it will be to
remain abstinent
144,145 and many (perhaps most) will
relapse within a short period.
Patients should be encouraged to remain on mainte-
nance and,when possible,alternative solutions sought for
issues like cost,eg,reducing frequency of visits,or explor-
ing insurance options.There is no adequate data on the
optimal length of time;each patient must be judged indi-
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history,and lifestyle stability.It is not uncommon to need
a number of episodes of opioid maintenance or even
long-term maintenance.
There is no consensus on the best way to withdraw from
buprenorphine maintenance other than to do it gradu-
ally,eg,2 mg/week until 4 mg is reached and then 1 mg
decreased every other week or monthly.Clonidine may
be useful in the final weeks to deal with the withdrawal
symptoms. Relapse back to illicit opioid use should be
taken seriously and the dose raised until the use stops.
Continued use should probably be handled by resuming
full-scale maintenance. As yet, there are no adequate
controlled studies comparing the ease or severity of with-
drawal from maintained buprenorphine vs methadone
patients, although earlier studies suggested that
buprenorphine withdrawal might be better tolerated.
146,147
Once the patient has completed detoxification, use of
naltrexone for at least 3 months may help prevent
relapse.The 1-month depot naltrexone is preferable,but
may be too expensive unless covered by insurance.
Naltrexone
Naltrexone was approved by the FDA as an opioid
antagonist in 1984.It is effective orally and is long-acting,
depending upon dose.While methadone blocks heroin
effects by cross-tolerance,naltrexone blocks the effects
by competitive antagonism at the µ receptor.The degree
of blockade is a function of the concentrations of agonist
to antagonist,and their receptor affinity.
Because of the blocking action of naltrexone,self-admin-
istration of opioids at usual doses produces no euphoria
so that either individuals cease heroin use or cease taking
the naltrexone.
148 Its long duration of action means that
naltrexone can be given two or three times per week,but
daily administration is usually preferred,both because of
developing a regular habit of use and of creating a higher
blockade. Less frequent administration is usually
employed when an individual is taking monitored doses.
Tolerance does not develop to the opioid antagonism,
even after almost 2 years of regular use.
149 The FDA
approved a 1-month acting depot preparation of naltrex-
one in 2006 for the treatment of alcoholism,
150 but it can be
used off-label for treatment of opioid dependence.
151
Dropout rates with naltrexone are high,but are signifi-
cantly better where there is substantial external motiva-
tion,such as in physicians whose performance is being
impaired,those involved with the criminal justice system,
and those facing loss of an important job.
152-156 Retention
is also better (43% at 6 months) in Russia,where addicts
are often young adults living with parents who monitor
intake and no agonist maintenance is permitted.
157
Clinical aspects
If naltrexone is given to an opioid-dependent individual,
it displaces the drugs from the receptor,producing rapid,
unpleasant withdrawal.To avoid this,5 to 7 days after the
last use of a short-acting opioid or 7 to 10 days after the
last dose of methadone is necessary before naltrexone
induction. Using one of the rapid withdrawal methods
described earlier can shorten the waiting period. Mild
symptoms of precipitated withdrawal can usually be
treated with clonidine and clonazepam.If sufficient absti-
nence is unclear, a test dose of a small amount of IM
naloxone (eg,0.2 mg) can be used.
157,159Any withdrawal
produced will be short-lived.Naltrexone should be initi-
ated with a dose of 25 mg and,if that produces no with-
drawal,the second 25-mg dose can be given 1 hour later.
If depot naltrexone is to be used,it is useful to have 1 to
2 days of a well-tolerated 50 mg oral dose.
For oral naltrexone,virtually 100% adherence is needed
because the blockade wears off around 24 to 48 hours
after the last dose. Missed doses often eventuate in
relapse,after which another detoxification and naltrex-
one induction is needed. Behavioral treatments have
been found to be helpful in improving naltrexone adher-
ence and treatment retention,doubling retention rates at
12 to 24 weeks.Approaches have included voucher incen-
tives contingent on pill-taking adherence and involve-
ment of family in monitoring such adherence.
160-165
When possible,all doses should be monitored either by
a family member or a health professional.Three times
per week dosing (100 mg,100 mg,150 mg) may be useful
if daily monitoring is difficult to arrange. Individuals
doing monitoring should be trained to look for “cheek-
ing”and other ways to avoid ingestion.Involvement in
self-help groups such as Alcoholics Anonymous or (AA)
or Narcotics anonymous (NA) should be encouraged.
While such groups usually oppose agonist maintenance,
naltrexone is often tolerated because of its lack of psy-
choactive effects.Urine tests should be carried out,if pos-
sible on a random basis,to see if the individual is using
opioids, suggesting missing naltrexone doses, or has
switched to drugs such as cocaine or benzodiazepines.
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Nausea, headache, and dysphoria have been reported,
especially during the first 4 weeks of naltrexone admin-
istration.These symptoms resemble mild protracted opi-
oid withdrawal and usually go away on their own or can
be ameliorated by clonidine. Elevated liver enzymes,
especially transaminases, were noted decades ago in
patients given high doses (eg, 300 mg/day) as experi-
mental obesity treatment.They reversed when the drug
was halted,as they have when occasionally observed in
patients taking normal doses.
166 If the enzymes are not
reduced, brief hospitalization to stop excess alcohol
intake or tests for such excessive drinking can be diag-
nostic.
167,168 Patients should be evaluated for viral hepati-
tis, which is very common among former IV users.
Because of the possibility of hepatic effects,baseline liver
function tests should be carried out.If abnormal (greater
than 3 to 5 times normal), naltrexone should not be
started.Monthly lab retests for the first 3 months can be
a useful precaution.
Although naltrexone affects a variety of endocrine func-
tions,
169-172 such effects have not been associated with par-
ticular problems.Likewise,although upregulation of opi-
oid receptors has been reported in rodents, it was not
found in a human study.Thus, the main risk of heroin
overdose post naltrexone appears to be from loss of tol-
erance.
148
Treatment of pain
When patients on naltrexone need analgesia, such as
after surgery or in emergency situations, nonsteroidal
anti-inflammatory drugs (NSAIDs,eg,Ketorolac) should
be tried. If not adequate, the blockade can be sur-
mounted by large doses of full agonists but this should
only be done in an environment where emergency ven-
tilation is available as in a hospital or emergency room
because of the danger of overdose.
Duration of maintenance
There are no clear guidelines on the duration of naltrexone
maintenance although,in general,6 to 12 months are prob-
ably a minimum depending on the circumstances.Careful
clinical evaluation of relapse risk should be done prior to
the decision to discontinue naltrexone.The 30-day depot
injection may improve compliance.Because naltrexone is
an antagonist, it can be stopped abruptly without with-
drawal symptoms.The high dropout rates and patient pref-
erence for agonist treatments will probably continue to
keep antagonists in a secondary role and in select popula-
tions unless agonist maintenance is not available.
173,174
Conclusion
Compared with other drugs of abuse,opioid dependence
benefits from a wider range of available pharmacological
tools for treatment.In spite of this,the large majority of
the 1 million heroin addicts and 2 to 3 million prescription
opioid abusers are not receiving treatment,and those who
enter often only seek detoxification, from which early
relapse is the most common outcome.The most successful
treatment is long-term maintenance on agonists such as
methadone and buprenorphine,but a variety of obstacles,
including government regulations,cost,availability,and
stigma, combine to diminish their use. The death rate
among heroin addicts is approximately 2% to 3% per
year,significantly higher than among their age- and socioe-
conomically matched cohorts.In addition to dealing with
the obstacles above,what is needed to decrease this are
new approaches that deal with the brain changes produced
by chronic dependence and could reverse the intracellular
changes related to addiction and craving.❏
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Tratamientos farmacológicos para la 
dependencia de opioides: opciones para la
detoxificación y el mantenimiento
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brales relacionados con la adicción.
Traitements pharmacologiques de la 
dépendance aux opioïdes : détoxification et
traitement d’entretien
Les traitements de la dépendance aux opioïdes, bien
que plus nombreux que ceux des autres substances
addictogènes, ne sont pas curatifs. Ils peuvent néan-
moins diminuer notablement les symptômes de
sevrage et la compulsion de consommation et blo-
quer les effets opioïdes dus aux récidives.
La méthode de sevrage la plus efficace est celle de la
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tés ou remplacer les agonistes s’ils ne sont pas dis-
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sevrage en la déclenchant par des antagonistes nar-
cotiques mais des problèmes  de tolérance ou de per-
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ment qui suit la détoxification.
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d’interventions psychosociales adaptées. Les patients
dont la motivation externe est forte pourront pré-
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